Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction

References

• Abraham EP, Chain E, Fletcher CM, et al. Further observations on penicillin. Lancet. 1941;238(6155):177–189.
   Google Scholar
• Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzæ. Br J Exp Pathol. 1929;10(3):226–236.
   Google Scholar
• Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature. 1940 Dec 01;146(3713):837.
   Google Scholar
• Berendonk TU, Manaia CM, Merlin C, et al. Tackling antibiotic resistance: the environmental framework [Perspective]. Nature Rev Microbiol. 2015 Mar 30;13:310.
   PubMed Web of Science ®Google Scholar
• O’Neill LJ. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist. 2014;20, 1–16.
   Google Scholar
• CDC. Achievements in public health, 1900–1999: control of infectious diseases. Morbidity and mortality weekly report. Published 1999. [cited 2018 Feb 7]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm. .
   Google Scholar
• Munita JM, Arias CA. Mechanisms of antibiotic resistance. Microbiol Spectr. 2016;4(2). doi:10.1128/microbiolspecVMBF-0016-2015.
   PubMed Web of Science ®Google Scholar
• Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014;6:25–64.
   PubMedGoogle Scholar
• Hassan M, Kjos M, Nes IF, et al. Natural antimicrobial peptides from bacteria: characteristics and potential applications to fight against antibiotic resistance. J Appl Microbiol. 2012 Oct;113(4):723–736.
   PubMed Web of Science ®Google Scholar
• WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug resistant bacterial infections, including tuberculosis. Essent Med Heal Prod. 2017. doi: WHO reference number: WHO/EMP/IAU/2017.12.
   Google Scholar
• Li Y, Sun Q-L, Shen Y, et al. Rapid increase in prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and emergence of colistin resistance gene mcr-1 in CRE in a hospital in Henan, China. J Clin Microbiol. 2018;56(4):e01932–17.
   PubMed Web of Science ®Google Scholar
• Conly J, Johnston B. Where are all the new antibiotics? The new antibiotic paradox. Can J Infect Dis Med Microbiol. 2005 May-Jun;16(3):159–160.
   PubMedGoogle Scholar
• Horowitz JB, Moehring HB. How property rights and patents affect antibiotic resistance. Health Econ. 2004 Jun 01;13(6):575–583.
   PubMed Web of Science ®Google Scholar
• Kerantzas CA, Jacobs WR. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. MBio. 2017;8(2):e01586–16.
   PubMed Web of Science ®Google Scholar
• Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016 Apr;19(4):CD003840.
   Google Scholar
• Chey WD, Leontiadis GI, Howden CW, et al. Correction: ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2018 Jul;113(7):1102.
   PubMed Web of Science ®Google Scholar
• Megraud F. The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy. Therap Adv Gastroenterol. 2012 Mar;5(2):103–109.
   PubMed Web of Science ®Google Scholar
• Liu A, Nicol E, Hu Y, et al. Tuberculous endocarditis. Int J Cardiol. 2013 Aug 10;167(3):640–645.
   PubMed Web of Science ®Google Scholar
• Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015 Nov 21;36(44):3075–3128.
   PubMed Web of Science ®Google Scholar
• Richman DD. HIV chemotherapy. Nature. 2001 Apr;410(6831):995–1001.
   PubMed Web of Science ®Google Scholar
• Cuevas JM, Geller R, Garijo R, et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol. 2015;13(9):e1002251–e1002251.
   PubMed Web of Science ®Google Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043.
   PubMed Web of Science ®Google Scholar
• Liu G-F, Li G-J, Zhao H. Efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic cancer: a network meta-analysis. J Cell Biochem. 2018 Jan 01;119(1):511–523.
   PubMed Web of Science ®Google Scholar
• McGuire S. World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO press, 2015. Adv Nutr. 2016;7(2):418–419.
   PubMed Web of Science ®Google Scholar
• Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124–4128.
   PubMed Web of Science ®Google Scholar
• Xu X, Xu L, Yuan G, et al. Synergistic combination of two antimicrobial agents closing each other’s mutant selection windows to prevent antimicrobial resistance. Sci Rep. 2018 May 08;8(1):7237.
   PubMedGoogle Scholar
• Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol. 2015 Oct 01;27:1–9.
   PubMed Web of Science ®Google Scholar
• Zhou A, Kang TM, Yuan J, et al. Synergistic interactions of vancomycin with different antibiotics against Escherichia coli: trimethoprim and nitrofurantoin display strong synergies with vancomycin against wild-type E. coli. Antimicrob Agents Chemother. 2015 Jan;59(1):276–281.
   PubMed Web of Science ®Google Scholar
• Vidaillac C, Benichou L, Duval RE. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012 Sep;56(9):4856–4861.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400.
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Prevention of drug resistance by combined drug treatment of tuberculosis. Handb Exp Pharmacol. 2012;211:87–98.
   PubMedGoogle Scholar
• Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care. 2011 Nov;23(1):48.
   Google Scholar
• Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis. 2003 Mar 1;36(5):615–621.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Neely M, Van Guilder M, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PLoS One. 2014;9(7):e101311.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu Y, Coates A. Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2019 Jan;63(1):e01630–18.
   PubMed Web of Science ®Google Scholar
• Tekin E, Beppler C, White C, et al. Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface. 2016;13:119.
   Web of Science ®Google Scholar
• Beppler C, Tekin E, Mao Z, et al. Uncovering emergent interactions in three-way combinations of stressors. J R Soc Interface. 2016 Dec;13(125):20160800.
   PubMedGoogle Scholar
• Tekin E, White C, Kang TM, et al. Prevalence and patterns of higher-order drug interactions in Escherichia coli. NPJ Syst Biol Appl. 2018;4:31.
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Pournaras S, Roilides E, et al. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010 Feb;54(2):602–609.
   PubMed Web of Science ®Google Scholar
• Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1983 May;11(5):427–433.
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003 Jul;52(1):1.
   PubMed Web of Science ®Google Scholar
• Soren O, Brinch KS, Patel D, et al. Antimicrobial peptide novicidin synergizes with rifampin, ceftriaxone, and ceftazidime against antibiotic-resistant enterobacteriaceae in vitro. Antimicrob Agents Chemother. 2015 Oct;59(10):6233–6240.
   PubMed Web of Science ®Google Scholar
• Lorenzo MP, Kidd JM, Jenkins SG, et al. In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium. J Antimicrob Chemother. 2019 Aug 1;74(8):2269–2273.
   PubMed Web of Science ®Google Scholar
• Lenhard JR, Thamlikitkul V, Silveira FP, et al. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. J Antimicrob Chemother. 2017 May 1;72(5):1415–1420.
   PubMed Web of Science ®Google Scholar
• Bulman ZP, Chen L, Walsh TJ, et al. Polymyxin combinations combat escherichia coli harboring mcr-1 and blaNDM-5: preparation for a Postantibiotic Era. MBio. 2017 Jul 25;8(4):e00540–17.
   PubMed Web of Science ®Google Scholar
• Hu Y, Pertinez H, Liu Y, et al. Bedaquiline kills persistent Mycobacterium tuberculosis with no disease relapse: an in vivo model of a potential cure. J Antimicrob Chemother. 2019 Jun 1;74(6):1627–1633.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019 Jan;39(1):10–39.
   PubMed Web of Science ®Google Scholar
• Loose, M, Naber, K.G, Hu, Y, et al. Serum bactericidal activity of colistin and azidothymidine combinations against mcr-1 positive colistin-resistant Escherichia coli. Int J Antimicrob Agents. 2018. doi: 10.1016/j.ijantimicag.2018.08.010
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013 Aug;57(3):349–358.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014 Sep;58(9):5598–5601.
   PubMed Web of Science ®Google Scholar
• Furtado GH, PA D, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007 Oct;30(4):315–319.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010 Feb;35(2):194–199.
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Kofteridis DP, et al. Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections. Infection. 2014 Aug;42(4):721–728.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically Ill patients with acinetobacter baumannii or Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2015 Oct;59(10):6575–6580.
   PubMed Web of Science ®Google Scholar
• Ribera A, Benavent E, Lora-Tamayo J, et al. Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus beta-lactams. J Antimicrob Chemother. 2015 Dec;70(12):3357–3365.
   Google Scholar
• Sorli L, Luque S, Segura C., et al. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis. 2017 Jan 5;17(1):11.
   PubMed Web of Science ®Google Scholar
• TL H, JS D.. Combination therapy for MRSA Bacteremia: to beta or Not to beta? Clin Infect Dis. 2019.
   Google Scholar
• Davis JS, Sud A, MVN O., et al. Combination of vancomycin and beta-lactam therapy for methicillin-resistant staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016 Jan 15;62(2):173–180.
   Google Scholar
• Tong SY, Nelson J, Paterson DL, et al. CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials. 2016 Mar 31;17:170.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Nov 8]. Available from: https://www.contagionlive.com/news/camera2-combination-therapy-for-mrsa-bacteremia-associated-with-higher-mortality-than-standard-care
   Google Scholar
• Lin JH. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr Drug Metab. 2007 Feb;8(2):109–136.
   PubMed Web of Science ®Google Scholar
• Hwang SY, Shin TG, Jo IJ, et al. Association between hemodynamic presentation and outcome in sepsis patients. Shock. 2014 Sep;42(3):205–210.
   PubMed Web of Science ®Google Scholar
• Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019 Jan 31;380(5):415–424.
   PubMed Web of Science ®Google Scholar
• Levy SB. Antibiotic resistance: an ecological imbalance. Ciba Found Symp. 1997;207:1–9. discussion 9–14.
   PubMedGoogle Scholar
• Ishii S. Ecology of pathogens and antibiotic-resistant bacteria in environments: challenges and opportunities. Microbes Environ. 2019;34(1):1–4.
   PubMed Web of Science ®Google Scholar
• Boiocchi F, Davies MP, Hilton AC. An examination of flying insects in seven hospitals in the United Kingdom and carriage of bacteria by true flies (Diptera: calliphoridae, Dolichopodidae, Fanniidae, Muscidae, Phoridae, Psychodidae, Sphaeroceridae). J Med Entomol. 2019 Oct 28;56(6):1684–1697.
   PubMed Web of Science ®Google Scholar
• Ignasiak K, Maxwell A. Antibiotic-resistant bacteria in the guts of insects feeding on plants: prospects for discovering plant-derived antibiotics. BMC Microbiol. 2017 Dec 1;17(1):223.
   PubMedGoogle Scholar
• Allen HK, Cloud-Hansen KA, Wolinski JM, et al. Resident microbiota of the gypsy moth midgut harbors antibiotic resistance determinants. DNA Cell Biol. 2009 Mar;28(3):109–117.
   PubMed Web of Science ®Google Scholar
• Zaura E, Brandt BW, Teixeira de Mattos MJ, et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio. 2015 Nov 10;6(6):e01693–15.
   PubMed Web of Science ®Google Scholar
• Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol. 2011 Oct;14(5):519–523.
   PubMed Web of Science ®Google Scholar
• Munck C, Gumpert HK, Wallin AI, et al. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci Transl Med. 2014 Nov 12;6(262):262ra156.
   PubMed Web of Science ®Google Scholar
• Acar JF. Antibiotic synergy and antagonism. Med Clin North Am. 2000 Nov;84(6):1391–1406.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Horinouchi T, Furusawa C. Acceleration and suppression of resistance development by antibiotic combinations. BMC Genomics. 2017 Apr 26;18(1):328.
   PubMedGoogle Scholar
• Zheng X, Berti AD, McCrone S, et al. Combination antibiotic exposure selectively alters the development of vancomycin intermediate resistance in staphylococcus aureus. Antimicrob Agents Chemother. 2018 Feb;62(2):e02100–17.
   PubMed Web of Science ®Google Scholar
• Zapata B, Alvarez DN, Farah S, et al. Prevention of high-level daptomycin-resistance emergence in vitro in streptococcus mitis-oralis by using combination antimicrobial strategies. Curr Microbiol. 2018 Aug;75(8):1062–1067.
   PubMed Web of Science ®Google Scholar
• Vestergaard M, Paulander W, Marvig RL, et al. Antibiotic combination therapy can select for broad-spectrum multidrug resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents. 2016 Jan;47(1):48–55.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012 Jul;25(3):450–470.
   PubMed Web of Science ®Google Scholar
• Zhao M, Bulman ZP, Lenhard JR, et al. Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2017 Jul 1;72(7):1985–1990.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Bello C. Antibiotic adjuvants - A strategy to unlock bacterial resistance to antibiotics. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4221–4228.
   PubMed Web of Science ®Google Scholar
• Lister PD. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy. 2000 Sep;20(9 Pt 2):213S–218S. discussion 224S-228S.
   PubMed Web of Science ®Google Scholar
• Ayres HM, Furr JR, Russell AD. Effect of permeabilizers on antibiotic sensitivity of Pseudomonas aeruginosa. Lett Appl Microbiol. 1999 Jan;28(1):13–16.
   PubMed Web of Science ®Google Scholar
• Denny B, West P, Panigrahi D. Effects of permeabilizers on antimicrobial susceptibility of Stenotrophomonas maltophilia and Acinetobacter spp. J Microbiol Immunol Infect. 2003 Mar;36(1):72–76.
   PubMedGoogle Scholar
• McMurry L, Petrucci RE Jr., Levy SB. Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A. 1980 Jul;77(7):3974–3977.
   PubMed Web of Science ®Google Scholar
• Unissa AN, Subbian S, Hanna LE, et al. Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016;45:474–492.
   PubMed Web of Science ®Google Scholar
• Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983 Jul-Aug;5(Suppl 3):S407–11.
   PubMedGoogle Scholar
• Kuck NA, Peets EA, Forbes M. Mode of action of ethambutol on Mycobacterium tuberculosis, strain H37R V. Am Rev Respir Dis. 1963 Jun;87:905–906.
   PubMedGoogle Scholar
• Zhang Y, Shi W, Zhang W, et al. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr. 2014 Aug;2(4):1. MGM2-0023-2013.
   Google Scholar
• Palomino JC, Martin A. Drug resistance mechanisms in mycobacterium tuberculosis. Antibiotics (Basel). 2014 Jul 2;3(3):317–340.
   PubMedGoogle Scholar
• Hu Y, Liu A, Ortega-Muro F, et al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo. Front Microbiol. 2015;6:641.
   PubMed Web of Science ®Google Scholar
• Graham DY, Qureshi WA, Antibiotic-resistant H. pylori infection and its treatment. Curr Pharm Des. 2000 Oct;6(15):1537–1544.
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol. 2003 Mar;98(3):562–567.
   PubMed Web of Science ®Google Scholar
• UNAIDS. Global aids up date 2016.. 2016. ISBN 978-92-9253-062-5
   Google Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525–1533.
   PubMed Web of Science ®Google Scholar
• Prieto-Vila M, Takahashi RU, Usuba W, et al. Drug resistance driven by cancer stem cells and their niche. Int J Mol Sci. 2017 Dec 1;18(12):2574.
   Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Toews ML, Bylund DB. Pharmacologic principles for combination therapy. Proc Am Thorac Soc. 2005;2(4):282–289. discussion 290-1.
   PubMedGoogle Scholar
• Sinel C, Cacaci M, Meignen P, et al. Subinhibitory concentrations of ciprofloxacin enhance antimicrobial resistance and pathogenicity of enterococcus faecium. Antimicrob Agents Chemother. 2017 May;61(5):e02763–16.
   PubMed Web of Science ®Google Scholar
• Scully M, Hassoun A. Increasing evidence of potential toxicity of a common antibiotic combination. J Infect Public Health. 2018 Jul - Aug;11(4):594–595.
   PubMed Web of Science ®Google Scholar
• Singh N, Yeh PJ. Suppressive drug combinations and their potential to combat antibiotic resistance. J Antibiot (Tokyo). 2017 Nov;70(11):1033–1042.
   PubMed Web of Science ®Google Scholar
• Rationalizing combination therapies. Nat Med. 2017 Oct 6;23(10):1113.
   PubMed Web of Science ®Google Scholar